Tertiary lymphoid structures (TLS) are clusters of immune cells that resemble and function
similarly to secondary lymphoid organs (SLOs). While TLS is generally associated with an …

Tumor-associated tertiary lymphoid structures (TLSs) are ectopic lymphoid formations within
tumor tissue, with mainly B and T cell populations forming the organic aggregates. The …

Despite the remarkable clinical success of immune checkpoint blockade (ICB) in the
treatment of cancer, the response rate to ICB therapy remains suboptimal. Recent studies …

Liver tumors, whether primary or metastatic, have emerged as a growing concern with
substantial global health implications. The timely identification and characterization of liver …

A combined therapy of atezolizumab and bevacizumab (atezo/bev) is used as the first-line
treatment for unresectable hepatocellular carcinoma (HCC). In this study, we report the case …

Tertiary lymphoid structure (TLS) can predict the prognosis and sensitivity of tumors to
immune checkpoint inhibitors (ICIs) therapy, whether it can be noninvasively predicted by …

Objective To develop a novel hybrid model for preoperative prediction of tertiary lymphoid
structures (TLSs) of hepatocellular carcinoma (HCC), and to identify patients who may …

Immune checkpoint inhibitors have opened an era of lung cancer therapy. However, a
notable disparity exists in the efficacy of immunotherapy among individual patients. The …

Background Tertiary lymphoid structures (TLS) within the tumor microenvironment have
been associated with cancer prognosis and therapeutic response. However, the …

The combination regimen of atezolizumab plus bevacizumab (Atezo/Bev) is currently used
as first-line treatment in patients with unresectable hepatocellular carcinoma. Herein, we …